Cidara Therapeutics Inc (CDTX)
14.08
+0.14
(+1.00%)
USD |
NASDAQ |
Nov 14, 11:16
Cidara Therapeutics Revenue (TTM): 39.07M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 39.07M |
| March 31, 2024 | 43.85M |
| December 31, 2023 | 61.50M |
| September 30, 2023 | 54.29M |
| June 30, 2023 | 82.32M |
| March 31, 2023 | 83.45M |
| December 31, 2022 | 64.45M |
| September 30, 2022 | 61.29M |
| June 30, 2022 | 27.63M |
| Date | Value |
|---|---|
| March 31, 2022 | 54.27M |
| December 31, 2021 | 49.57M |
| September 30, 2021 | 46.08M |
| June 30, 2021 | 41.42M |
| March 31, 2021 | 11.94M |
| December 31, 2020 | 12.07M |
| September 30, 2020 | 10.15M |
| June 30, 2020 | 26.84M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
10.15M
Minimum
Sep 2020
83.45M
Maximum
Mar 2023
45.30M
Average
46.08M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Arbutus Biopharma Corp | 6.742M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 173.82M |
| Cue Biopharma Inc | 8.296M |